Blue Jet Healthcare Limited has informed the Exchange regarding a press release dated July 22, 2025, titled "For the Financial Results for the quarter ended June 30, 2025".
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Blue Jet Healthcare reported Q1 FY26 revenue of Rs. 3,548 million, up 117.8% year-on-year (YoY) but only 4.2% quarter-on-quarter (QoQ). EBITDA came in at Rs. 1,210 million, up 173.3% YoY but down 13.6% QoQ, with margins at 34.1% (up 693 bps YoY, down 701 bps QoQ). Profit after tax stood at Rs. 912 million, up 141.3% YoY but down 17.2% QoQ, with PAT margin at 25.7%. The strong YoY growth was driven by ramp-up in the PI (Pharmaceutical Intermediates) and API product categories. The QoQ decline was mainly due to a drop in gross margin to 48.4% from 54.7%, caused by a shift in product mix and lower inventory levels reducing overhead absorption. The company is a CDMO specializing in contrast media intermediates (supplying GE Healthcare, Guerbet, Bracco) and high-intensity sweeteners (supplying Colgate Palmolive, Unilever).
Very strong YoY growth signals a major business expansion, but the QoQ dip in margins and profits may cause near-term investor caution. Long-term outlook looks positive given capacity expansion plans, R&D investments, and a strong product pipeline.